An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer

ConclusionAlthough each of the articles contributed their own analytic strengths and limitations, the overall quality of the studies was moderate. The review demonstrated that the vast majority of the reported incremental cost-effectiveness ratios exceeded the typically employed willingness to pay thresholds used in each country of analysis. Only three of the reviewed articles studied chemotherapies rather than treatments targeting either HER2 or hormone receptors, demonstrating a gap in the literature.

Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research